What is the price target for SNDX stock?
20 analysts have analysed SNDX and the average price target is 40.99 USD. This implies a price increase of 66.34% is expected in the next year compared to the current price of 24.64.
SYNDAX PHARMACEUTICALS INC (SNDX) Forecast, Price Target & Analyst Ratings
NASDAQ:SNDX • US87164F1057
Current stock price
24.64 USD
+0.35 (+1.44%)
At close:
24.64 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SYNDAX PHARMACEUTICALS INC (SNDX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.62
- Revenue Estimate
- 74.12M
Price Target Details & History
Consensus Price Target and Range
Mean target
$40.99
Upside
+ 66.34%
From current price of $24.64 to mean target of $40.99, Based on 20 analyst forecasts
Low
$28.28
Median
$38.76
High
$59.85
Price Target Revisions
1 Month
2.02%
3 Months
2.22%
Price Target Summary
20 Wall Street analysts provided a forecast for the next 12 months for SNDX. The average price target is 40.99 USD. This implies a price increase of 66.34% is expected in the next year compared to the current price of 24.64.
The average price target has been revised upward by 2.22% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
87.00%
SNDX was analyzed by 20 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about SNDX.
In the previous month the buy percentage consensus was at a similar level.
SNDX was analyzed by 20 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-01 | Goldman Sachs | Maintains | Buy -> Buy |
| 2026-03-31 | Mizuho | Maintains | Outperform -> Outperform |
| 2026-03-09 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-03-02 | Citigroup | Maintains | Buy -> Buy |
| 2026-01-27 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-12-09 | BTIG | Reiterate | Buy -> Buy |
| 2025-11-24 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-04 | UBS | Maintains | Buy -> Buy |
| 2025-11-04 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-27 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-19 | BTIG | Reiterate | Buy -> Buy |
| 2025-09-10 | Stifel | Reiterate | Buy |
| 2025-09-05 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-09-04 | Guggenheim | Initiate | Buy |
| 2025-08-05 | BTIG | Maintains | Buy -> Buy |
| 2025-08-05 | Citigroup | Maintains | Buy -> Buy |
| 2025-07-15 | UBS | Maintains | Buy -> Buy |
| 2025-07-10 | Goldman Sachs | Initiate | Buy |
| 2025-05-06 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-05-06 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2025-03-20 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-03-04 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-03-04 | Citigroup | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.62
- Revenue Estimate
- 74.12M
- Revenue Q2Q
- 269.82%
- EPS Q2Q
- 36.57%
- Number of Analysts
- 13
Next Earnings Revisions
Revenue (1 Month)
3.33%
Revenue (3 Months)
8.20%
EPS (1 Month)
-11.85%
EPS (3 Months)
-2.00%
Next Earnings Summary
SNDX is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -0.62 USD and the consensus revenue estimate is 74.12M USD.
The next earnings revenue estimate has been revised upward by 8.2% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 23.68M | 172.352M 627.84% | 356.69M 106.95% | 502.71M 40.94% | 694.91M 38.23% | 931.31M 34.02% | 1.111B 19.29% | 1.386B 24.75% | 1.591B 14.79% | 1.291B -18.86% | ||
| EBITDA YoY % growth | -229.942M -51.51% | -339.664M -47.72% | -273.078M 19.60% | -143.119M 47.59% | -35.018M 75.53% | 123.7M 453.25% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -229.954M -51.48% | -339.672M -47.71% | -273.084M 19.60% | -131.755M 51.75% | -18.485M 85.97% | 108.17M 685.16% | 316.12M 192.24% | 461.08M 45.86% | 779.64M 69.09% | 992.87M 27.35% | 564.77M -43.12% | |
| Operating Margin | N/A | -1,434.43% | -158.45% | -36.94% | -3.68% | 15.57% | 33.94% | 41.50% | 56.25% | 62.41% | 43.75% | |
| EPS YoY % growth | -2.96 -20.82% | -3.73 -26.01% | -3.29 11.80% | -1.58 52.05% | -0.22 85.92% | 1.02 558.19% | 2.47 142.35% | 3.48 40.94% | 5.25 51.12% | 6.55 24.72% | 4.62 -29.48% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.62 36.57% | -0.51 38.11% | -0.45 36.35% | -0.23 71.05% | -0.57 8.12% | -0.56 -9.01% | -0.45 -1.19% | -0.46 -104.19% |
| Revenue Q2Q % growth | 74.12M 269.82% | 85.747M 125.90% | 96.315M 109.97% | 114.61M 66.76% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | -51.108M 38.80% | -40.566M 41.51% | -35.845M 37.58% | 4.231M 106.77% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -47.828M 42.73% | -36.894M 46.80% | -30.068M 47.64% | -5.744M 90.82% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
32.18%
EPS Next 5 Year
25.04%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
59.76%
Revenue Next 5 Year
45.49%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
35.00%
EBIT Next 5 Year
N/A
SYNDAX PHARMACEUTICALS INC / SNDX Forecast FAQ
What is the next earnings date for SNDX stock?
SYNDAX PHARMACEUTICALS INC (SNDX) will report earnings on 2026-05-04.
What are the consensus estimates for SNDX stock next earnings?
The consensus EPS estimate for the next earnings of SYNDAX PHARMACEUTICALS INC (SNDX) is -0.62 USD and the consensus revenue estimate is 74.12M USD.
What is the expected long term growth rate for SYNDAX PHARMACEUTICALS INC (SNDX)?
The expected long term growth rate for SYNDAX PHARMACEUTICALS INC (SNDX) is 59.76%.